Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Intercept Pharmaceuticals, Inc. and Lead Plaintiff Deadline of April 22, 2014 - WECT TV6-WECT.com:News, weather & sports Wilmington, NC

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Intercept Pharmaceuticals, Inc. and Lead Plaintiff Deadline of April 22, 2014

  • HealthMore>>

  • FDA to propose e-cigarette regulations

    FDA to propose e-cigarette regulations

    © FDA© FDA
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
  • 1 in 13 U.S. schoolkids takes psych meds

    1 in 13 U.S. schoolkids takes psych meds

    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>
    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Bronstein, Gewirtz & Grossman, LLC

NEW YORK, Feb. 24, 2014 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC announces that a securities class action has been filed in the United States District Court for the Southern District of New York on behalf of those who purchased shares of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NasdaqGS: ICPT ), during the period between January 9, 2014 and January 10, 2014, inclusive (the "Class Period").

The complaint charges Intercept and certain of its executives with violations of federal securities laws.  On January 9 and 10, 2014, Intercept announced that its Phase 2 trial of its primary drug compound obeticholic acid had been stopped early based on an interim analysis that showed that the efficacy endpoint of the trial had been met.

Then, on Friday, January 10, 2014, after the markets closed, the National Institutes of Health issued a written statement revealing that, while the efficacy primary endpoint in the study had already been met, participants in the study who received the drug suffered disproportionate levels of lipid abnormalities. On this news, Intercept stock dropped from its $445.83 per share closing price on January 10, 2014, to a closing price of $255.12 per share on January 14, 2014.

Plaintiff seeks to recover damages on behalf of all Intercept shareholders who purchased common stock during the Class Period described above.  

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. April 22, 2014 is the deadline for investors to seek a lead plaintiff appointment.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow